MedPath

Evaluation of Microcirculation of Peripheral Vascular Disease in Diabetes

Phase 1
Conditions
Peripheral Vascular Disease in Diabetes
Registration Number
NCT03528811
Lead Sponsor
Shanghai 10th People's Hospital
Brief Summary

The main aim of the present study was to evaluate the microcirculation of peripheral vascular disease in diabetes.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
300
Inclusion Criteria
  • 1.Patients with Peripheral vascular disease with or without diabetes. 2.Rutherford class 2-6. 3.Target lesions with a diameter reduction of at least 50% on angiography, and without past history of any intervention.

    4.Target vessel with 2.0--10.0mm in diameter and having a lesion of about 4cm-20cm in length.

    5.Written informed consent signed by the patients or representatives

Exclusion Criteria
  • 1.Previous bypass surgery or stent placement at the ipsilateral lower limb 2.History of intolerance to antiplatelet therapy, heparin, or contrast media. 3.Bleeding diathesis; 4.Active systemic bacterial infection; 5.Severely impaired renal function (serum creatinine level > 2.5 mg/dL. Expected survival time of less than 24 months

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Coincidence rate of "5 points test of Tongji university"12 months

The primary study endpoint was that the coincidence rate of evaluating the microcirculation by the newly-established "5 points test of Tongji university" attains over 95% before and after operations as assessed by digital substraction angiography (DSA).

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Shanghai Tenth People's Hospital, Tong ji University

🇨🇳

Shanghai, China

Shanghai Tenth People's Hospital, Tong ji University
🇨🇳Shanghai, China
Mao Q Li, Ph.D
Contact
02166313506
cjr.limaoquan@vip.163.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.